Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
Among oncolytic viruses, the vesicular stomatitis virus (VSV) is especially potent and a highly promising agent for the treatment of cancer. But, even though effective against multiple tumor entities in preclinical animal models, replication-competent VSV exhibits inherent neurovirulence, which has...
Main Authors: | Muik, Alexander, Dold, Catherine, Geiß, Yvonne, Volk, Andreas, Werbizki, Marina, Dietrich, Ursula, von Laer, Dorothee |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer-Verlag
2012
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396339/ |
Similar Items
-
ONCOLYTIC VIROTHERAPY
by: Russell, Stephen J, et al.
Published: (2012) -
Oncolytic Virotherapy for Hematological Malignancies
by: Bais, Swarna, et al.
Published: (2012) -
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
by: Simovic, Boris, et al.
Published: (2015) -
Oncolytic Virotherapy of Canine and Feline Cancer
by: Gentschev, Ivaylo, et al.
Published: (2014) -
Oncolytic virotherapy for advanced liver tumours
by: Chang, Ju-Fang, et al.
Published: (2009)